Drug delivery strategies for the treatment of Helicobacter pylori infections

Current Pharmaceutical Design

Volumn 11, Issue 6, 2005, Pages 775-790

  Conway, B R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Adjuvants; Antibiotic; Drug delivery; Floating dosage forms; Gastric retention; Helicobacter pylori; Mucoadhesion; Vaccines

Indexed keywords

ALGINIC ACID; ALUMINUM HYDROXIDE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BISMUTH; BISMUTH BISKALCITRATE; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH NITRATE; CASEIN; CLARITHROMYCIN; DRUG ADDITIVE; GELATIN; HELICIDE; HYDROXYPROPYLCELLULOSE; METRONIDAZOLE; MICROSPHERE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; POLYACRYLIC ACID; PRONASE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; SUCRALFATE; SUCROSE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ADHESION; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHRONIC GASTRITIS; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RETENTION; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYDRODYNAMICS; IMMUNE RESPONSE; INFECTION PREVENTION; MEDICAL TECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; REINFECTION; REVIEW; SIDE EFFECT; STOMACH EPITHELIUM; STOMACH LYMPHOMA; STOMACH MUCOSA; STOMACH MUCUS; STOMACH ULCER; TURNOVER TIME;

ANTI-INFECTIVE AGENTS; DRUG DELIVERY SYSTEMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH; VACCINATION;

EID: 14844298604     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381819     Document Type: Review

References (177)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315.
2. Petersen WL. Helicobacter pylori and peptic ulcer disease. N Eng J Med 1991; 324: 1043-1048.
3. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-741.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186.
5. WHO The World Health Report 1996 - Fighting disease, fostering development, 1996 published by World Health Organization, Geneva.
6. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020-global burden of disease study. Lancet 1997; 349: 1498-1504.
7. Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003; 5: 693-703.
8. Rothenbacher D, Bode G, Berg G, Knayer U, Gonser T. Adler G. Brenner H. Helicobacter pylori among pre-school children and their parents: evidence for parent-child transmission. J Infect Dis 1999; 179: 398-402.
9. Velaquez M, Feirtag JM. Helicobacter pylori: characteristics, pathogenicity, detection methods and mode of transmission implicating food and water. Int J Food Microbiol 1999; 53: 95-104.
10. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterol 2000; 118: S2-S8.
11. Farthing MJG. Helicobacter pylori infection: an overview. Br Med Bull 1998; 54: 1-6.
12. Owen RJ. Helicobacter-species classification and identification. Br Med Bull 1998; 54: 17-30.
13. Kulpers EJ, Janssen MJR, de Boer WA. Good bugs and bad bugs: indications and therapies for Helicohacter pylori eradication. Curr Opin Pharmacol 2003; 3: 480-485.
14. Huang J-Q, Hunt RH. Review: eradication of Helicobacter pylori. Problems and recommendations. J Gastroenterol Hepatol 1997; 12: 590-598.
15. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastrooesophageal reflux disease. Gastroenterol 2001; 121: 1120-1126.
16. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. (Cochrane Review). In: The Cochrane Library, Issue 2, 2004 Chichester, UK: John Wiley & Sons, Ltd.
17. Bazzoli F, Bianch Porro G, Maconi G, Molteni M, Pozzaro P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Digest Liv Dis 2002; 34: 70-83.
18. Megraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicob Agents 2000; 16: 507-509.
19. Houben MHMG, Van de Beek D, Hensen EF, De Craen AJM, Rauws EAJ, Tytgat GNJ. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-1055.
20. Megraud F. Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist Updat 2001; 4: 18-186.
21. Lahrej RJF, Van Rossum LGM, Jansen JBMJ, Straatman H, Verbeek ALM. Evaluation of treatment regimes to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-864.
22. Frenck Jr RW, Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5: 705-713.
23. Borody TJ, Anrews P, Fracchia G, Brandl S, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter-pylori Gut 1995; 37: 477-471.
24. Laine LH, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567.
25. Realdi G, Dore MP, Atzei A, Carta M, Piana A, Manca A, et al. New therapy for Helicobacter pylori: omeprazole-metronidazole-tetracycline and the effect of tetracycline resistance. Gastroeneterology 1998; 114: G1092
26. Nakamura M, Spiller RC, Barrett DA, Wibawa JID, Kumagai N, Tsuchimoto K, et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and claithromycin triple therapy. Helicobacter 2003; 6: 294-299.
27. Adamek RJ, Opferkuch W, Pfaffenbach B, Wegener M. Cure of Helicobacter pylori infection: Role of duration of treatment with omeprazole and amoxicillin. Am J Gastroenterol 1996; 91: 98-100.
28. Logan RP. Adherence of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10 (Suppl 1): 3-15.
29. Kim JH, Park YS, Kim YS, Hahm KB, Lee SI. Detection of Helicobacter pylori in gastric tissue by in situ hybridisation. Gatroenterol 1995; 108: A131.
30. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterol 1996; 111: 358-367.
31. Ortiz RAM, Calafatti SA, Corazzi A, Souza JM, Deguer M, DeSouza CAF, et al. Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole. Aliment Pharmacol Ther 2002; 16: 1163-1170.
32. Goddard AF, Erah PO, Barrett DA, Shaw PN, Spiller RC. The effect of protein binding and lipophilicity of penicillins on their in-vitro flux across gastric mucosa. J Antimicob Chemother 1998; 41: 231-236.
33. Sherwood PV, Wibawa JI, Fowkes DP, Goddard AF, Barrett DA, Shaw PN, et al. Gastric amoxicillin transfer in Helicobacter pylori positive patients: effect of bile reflux. Gastroenterol 2000; 118 Suppl 2:5960.
34. Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol 2002; 54: 341-347.
35. Pedrazzoli J, Calafatti SA, Ortiz RAM, Dias FE, Deguer M, Mendes FD, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001; 36: 1248-1253.
36. Atherton JC, Cullen DJE, Kirk GE, Hawkey CJ, Spiller RC. Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Aliment Pharmacol Ther 1996; 10: 631-635.
37. Lozniewski A, de Korwin JD, Muhale F, Jehl F. Gastric diffusion of antibiotics used against Helicobacter pylori. Int J Antimicrob Agent 1998; 9: 181-193.
38. Goddard AF. Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther 1998; 12: 1175-1184.
39. Lozniewski A, Duprez A, Renault C, Muhale F, Conroy MC, Weber M, et al. Gastric penetration of amoxicillin an a human Helicobacter pylori- infected model. Antimicrob Agents Chemother 1999; 43: 1909-1913.
40. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
41. Hirschl AM, Rotter ML. Amoxicillin for the treatment of Helicobacter pylori infection. J Gastroenterol 1996; 31 S9: 44-47.
42. Kimura K, Ido K, Saifuku K, Taniguchi Y, Kihira K, Satoh K, et al. A 1-h topical therapy for the treatment of Helicobacter-pylori infection. Am J Gastroenterol 1995; 90: 60-63.
43. Yokel RA, Dickey KM, Goldberg AH. Selective adherence of a sucralfate-tetracycline complex to gastric-ulcers - implications for the treatment of Helicobacter-pylori. Biopharm Drug Dispos 1995; 16: 475-479.
44. Higo S, Ori K, Takeuchi H, Yamamoto H, Hino T, Kawashima Y. A novel evaluation method of gastric mucoadhesive property in vitro and the mucoadhesive mechanism of tetracycline-sucralfate acidic complex for eradication of Helicobacter pylori. Pharm Res 2004; 21: 413-419.
45. Hwang S-J, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15: 243-284.
46. Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003; 20: 461-497.
47. Washington N, Washington C, Wilson CG. In: Physiological Pharmaceutics. Barriers to drug absorption. Second edition. London, Taylor and Francis 2001; 75-108.
48. Atherton JC, Washington N, Bracewell MA, Sutton LJ, Greaces JL, Perkins AC, et al. Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Aliment Pharmacol Ther 1994; 8: 489-494.
49. Reddy LHV, Murthy RSR. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst 2002; 19: 553-585.
50. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel 2000; 63: 235-259.
51. Yang LB, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Rel 1999; 57: 215-222.
52. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate. Int J Pharm 1992; 86: 79-88.
53. Bulgarelli E, Forni F, Bernabi MT. Effect of matrix composition on casein-gelatin beads floating properties. Int J Pharm 2000; 198: 157-165.
54. Lee J-H, Park TG, Choi H-K, Development of oral drug delivery system using floating microspheres. J Microencap 1999; 16: 715-729.
55. Murata Y, Sasaki N, Miyamoto E, Kawasaki S. Use of floating alginate beads for stomach-specific delivery. Eur J Pharm Biopharm 2000; 50: 221-226.
56. Gable CG. In: Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. London, Pharmaceutical Press, 2001.
57. Iannuccelli V, Coppi G, Sansone R, Ferolla G. Air compartment multiple-unit system for prolonged gastric residence. Int J Pharm 1998; 174: 55-62.
58. Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J Microencap 2003; 20: 239-347.
59. Whitehead L, Fell JT, Collett, JH, Sharm HL, Smith A-M. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Rel 1998; 55: 3-12.
60. Whitehead L, Collett, JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000; 210: 45-49.
61. Umamaheshwari RB, Jain S, Tripathi PK, Agarwal GP Jain NK. Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori. Drug Deliv 2002; 9: 223-231.
62. Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm Pharmacol 2003; 55: 1607-1613.
63. Ohta T, Shibata H, Kawamori T, Iimuro M, Sugimura T, Wakabayashi K. Marked reduction of Helicobacter pylori-induced gastritis by urease inhibitors, acetohydroxamic acid and flurofamide, in Mongolian gerbils. Biochem Biophys Res Commun 2001; 285: 728-733.
64. Peppas NA, Sahlin JJ. Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials 1996; 17: 1553-1561.
65. Tur KM, Ch'ng H-S. Evaluation of possible mechanism(s) of bioadhesion. Int J Pharm 1999; 160: 61-74.
66. Hudson SM, Jenkins DW. Chitin and Chitosan. In: Encylopedia of polymer science and technology-online. John Wiley and Sons 2001.
67. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumira R, Barisal K, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004; 274: 1-33.
68. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Rel 2003; 89: 151-165.
69. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992; 78: 43-48.
70. Gaserød O, Joliffe AG, Hampson FC, Dettmar PW, Skjåk-Bræk G. The enhancement of the bioadhesive properties of alginate gel beads by coating with chitosan. Int J Pharm 1998; 175: 237-246.
71. Gupta KC, Kumar MNVR. Drug release behavior of beads and microgranules of chitosan. Biomaterials 2000; 21: 1115-1119.
72. Chandy T, Sharma CP. Chitosan matrix for oral sustained delivery of ampicillin. Biomaterials 1993; 14: 939-944.
73. Shu YZ, Zhu KJ, Song W. Novel pH-sensitive citrate cross-linked chitosan film for drug controlled release. Int J Pharm 2001; 212: 19-28.
74. Shu YZ, Zhu KJ. Controlled drug release properties of ionically cross-linked chitosan beads: the influence of anion structure. Int J Pharm 2002; 233: 217-225.
75. Sugimoto K, Yoshida M, Yata T, Higaki K, Kimura T. Evaluation of poly(vinyl alcohol)-gel spheres containing chitosan as dosage form to control gastrointestinal transit time of drugs. Biol Pharm Bull 1998; 21: 1202-1206.
76. Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation for biomedical applications. Eur J Pharm Biopharm 2004; 57: 35-52.
77. Remunãn-Lopez C, Portero A, Lemos M, Vila-Jato JL, Nunez MJ, Riveiro P, et al. Chitosan microspheres for the specific delivery of amoxycillin to the gastric cavity. STP Pharma Sci 2000; 10: 69-76.
78. Sakkinen M, Marvola J, Kanerva H, Lindevall K, Lipponen M, Kekki T, et al. Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. Eur J Pharm Biopharm 2004; 57: 133-143.
79. Mi FU, Wong TB, Shyu SS. Sustained release of oxytetracycline from chitosan microspheres prepared by interfacial acylation and spray hardening methods. J Microencap 1997; 14: 577-591.
80. Shah S, Qaqish R, Patel V, Amiji MM, Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol 1999; 51: 667-672.
81. Hejazi R, Amiji M. Stomach-specific anti-H-pylori therapy. I. Preparation and characterisation of tetracycline-loaded chitosan microspheres. Int J Pharm 2002; 235: 87-94.
82. Hejazi R, Amiji M. Stomach-specific anti-H-pylori therapy. II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Technol 2003; 8: 253-262.
83. Portero A, Remunan-Lopez, Criado MT, Alonso MJ. Reacetylated microspheres for controlled delivery of anti-microbial agents to the gastric mucosa. J. Microencap 2003; 19: 797-809.
84. Hejazi R, Amiji M. Stomach-specific anti-H-pylori therapy. III. Effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils. Int J. Pharm 2004; 272: 99-108.
85. Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y, Shibata K, et al. Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pylori. Biol Pharm Bull 1999; 22: 55-60.
86. Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microsphres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res 1995; 12: 397-405.
87. Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxicllin for clearance of Helicobacter pylori. Antimicrob Agents Chemother 1998; 42: 2492-2494.
88. Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. Amoxicillin-loaded polyethylcyanacrylate nanopraticle: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001; 22: 2857-2865.
89. Wang J, Tauchi Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for eradication of H pylori. Drug Deliv 2000; 7: 237-243.
90. Singla AK, Chawla M, Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev Ind Pharm 2000; 26: 913-924.
91. Roldo M, Hornof M, Caliceti P, Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm 2004; 57: 115-121.
92. Tapia C, Escobar Z, Costa E, Sapag-Hagar J, Valenzuela F, Basualto C, et al. Comparative studies in polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem chlorhydrate release systems. Eur J Pharm Biopharm 2004; 57: 65-75.
93. Naisbett N, Woodley J. The potential use of tomato lectin for oral drug delivery: 3. Bioadhesion in vivo. Int J Pharm 1995; 114: 227-236.
94. Lehr C-M. Lectin-mediated drug delivery: The second generation of bioadhesives. J Control Rel 2000; 65: 19-29.
95. Irache JM, Durrer C, Duchene D, Ponchel G. Preparation and characterisation of lectin-latex conjugates for specific bioadhesion. Biomaterials 1994; 15: 899-904.
96. Montisci M-J, Dembri A, Giovannuci G, Chacun H, Duchene D, Ponchel G. Gatrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum and Lotus tetragonobulus lectin-PLA microsphere conjugates in rats. Pharm Res 2001; 18; 829-837.
97. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Del Rev 2004; 56: 459-480.
98. Umamaheshwari RB, Jain S, Jain NK. Site-specific drug delivery of acetohydroxamic acid for the treatment of H. pylori. STP Pharm Sci 2003; 12: 41-48.
99. Anand V, Kandarapu R, Garg S. Ion-exchange resins: carrying drug delivery forward. Drug Discov Today 2001; 6: 905-914.
100. Washington N, Wilson CG, Greaves JL, Norman S, Peach JM, Pugh K. A gamma-scintigraphic study of gastric coating by Expidet, tablet and liquid formulations. Int J Pharm 1989; 57: 17-22.
101. Burton S, Washington N, Steele RJC, Musson R, Feely L. Intragastric distribution of ion-exchange resins: A drug delivery system for the topical treatment of the gastric mucosa. J Pharm Pharmacol 1995; 47: 901-906.
102. Park K, Robinson JR. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int J Pharm 1984; 19: 107-127.
103. Park K, Robinson JR. Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion. J Control Release 1985; 2: 47-57.
104. Thairs S, Ruck S, Jackson SJ, Steele RJC, Feely LC, Washington C, et al. Effect of dose size, food and surface coating on the gastric residence and distribution of an ion exchange resin. Int J Pharm 1988; 176: 47-53.
105. Cuna M. Alonso MJ, Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm 2001; 51: 199-205.
106. Jackson SJ, Bush D, Perkins AC. Comparative scintigraphic assessment of the intragastric distribution and resistice of cholestyramine, Carbopol 934P and sucralfate. Int J Pharm 2001; 212: 55-62.
107. Jackson SJ, Bush D, Washington N, Perkins AC. Effect of resin surface charge on gastric mucoadhesion and residence for cholestyramine. Int J Pharm 2000; 205: 173-181.
108. Atyabi F, Sharma HL, Mohammad HAH, Fell JT. Controlled drug release from coated floating ion exchange resin beads. J Control Release 1996; 42: 25-28.
109. Atyabi F, Sharma HL, Mohammad HAH, Fell JT. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J Control Release 1996; 42: 105-113.
110. Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv 2003; 10: 151-160.
111. Salessiotis N. Measurement of the diameter of the pylorus in man. I. Experimental project for clinical application. Am J Surg 1972; 124: 331-333.
112. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90: 143-162.
113. Roy I, Gupta MN. Smart polymeric materials: emerging biochemical applications. Chem Biol 2003; 10: 1161-1171.
114. Verestuic L, Ivanov C, Barbu E, Tsiboulklis J. Dual-stimuli-responsive hydrogels based on poly(N-isopropylacrylamide)/chitosan semi-interpenetrating networks. Int J Pharm 2004; 269: 185-194.
115. Kim YH, Bae YH, Kim SW. pH/temperature-sensitive polymers for macromolecular drug loading and release. J Control Release 1994; 28: 143-152.
116. Serres A, Baudys M, Kim SW. Temperature and pH-sensitive polymers for human calcitonin delivery. Pharm Res 1996; 13: 196-201.
117. Kurisawa M, Yui N. Dual-stimuli-responsive drug release from interpenetrating polymer network-structured hydrogels of gelatin and dextran. J Control Release 1998; 54: 191-200.
118. Ruel-Gariépy E, Leclair G, Hildgen P, Gupta A, Leroux J-C. Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release 2002; 82: 373-383.
119. Bajpai AK, Bajpai J, Shukla S. Release dynamics of tetracycline from a loaded semi-interpenetrating polymeric material of polyvinyl alcohol and poly(acrylamide-co-styrene). J Mater Sci Mater Med 2003; 14: 347-357.
120. Bayramoglu G, Arica MY. A novel pH sensitive porous membrane carrier for various biomedical applications based on pHEMA/chitosan: Preparation and its drug release characteristics. Macromolecular Symposia 2003; 203: 213-218.
121. de la Torre PM, Enobakhare Y, Torrado G, Torrado S. Release of amoxicillin from polyionic complexes of chitosan and poly(acrylic acid). Study of polymer/polymer and polymer/drug interactions within the network structure. Biomaterials 2003; 24: 1499-1506.
122. Torrado S, Prada P, de la Torre PM, Torrado S. Chitosanpoly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. Biomaterials 2004; 25: 917-923.
123. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites. J Control Release 2000; 64: 39-51.
124. Patel VR, Amiji MM. Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Pharm Res 1996; 13: 588-593.
125. Risbud MV, Hardikar AA, Bhat SV and Bhonde RR. pH-sensitive freeze-dried chitosan-polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery. J Control Release 2000; 68: 23-30.
126. Kim D, Park K. Swelling and mechanical properties of superporous hydrogels of poly (acrylamide-co-acrylic acid)/polyethylenimine interpenetrating polymer networks. Polymer 2004; 45: 189-196.
127. Dorkoosh FA, Verhof JC, Stokkel MPM, Blok D, Borchard G, Rafiee-Tehrani M, et al. Feasibility study in human volunteers on the retention of superporous hydrogels in the intestinal tract using g-scintigraphy. Controlled Rel Society 30th Annual Meeting 2003; 575.
128. Polnok A, Verhoef JC, Borchard G, Sarisuta N, Junginger HE. In vitro evaluation of intestinal absorption of desmopressin using drug-delivery systems based on superporous hydrogels. Int J Pharm 2004; 269: 303-310.
129. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002; 19: 1516-1523.
130. Klausner EA, Lavy E, Friedman M, Hoffman A. Novel levodopa gastroretentive dosage forms: in vivo evaluation in dogs. J Control Rel 2003; 88: 117-126.
131. Klausner EA, Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M, et al. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharmacol 2003; 43: 711-720.
132. Gotoh A, Akamatsu, T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Heliocbacter 2002; 7: 183-191.
133. Nakao M, Miyagawa K, Nakano Y, Sakane T, Tada M, Nishimura O, et al. Pyloricidins, novel anti-Helicobacter pylori antibiotics produced by Bacillus sp. I. Taxonomy, fermentation and biological activity. J Antibiot 2001; 54: 926-933.
134. Sorba G, Bertinaria M, Di Stilo A, Gasco A, Scaltrito MM, Brenciaglia MI, et al. Anti-Helicobacter pylori agents endowed with H2-antagonist properties. Bioorg Med Chem Lett 2001; 11: 403-406.
135. Hamilton-Müller JMT. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003; 22: 360-366.
136. Sutton P, Doidge C. Helicobacter vaccines spiral into the new millennium. Dig Liver Dis 2003; 25: 675-687.
137. Chen H. Recent advantages in mucosal vaccine development. J Control Release 2000; 67: 11-128.
138. Svennerholm A-M. Prospects for a mucosally-administered vaccine against Helicobacter pylori. Vaccine 2003; 21: 347-353.
139. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987; 7: 265-276.
140. Hanes J, Cleland JL, Langer R. New advances in microsphere-based single-dose vaccines. Adv Drug Del Rev 1997; 28: 97-119.
141. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Sys 2002; 19: 73-98.
142. Varde NK, Pack DW. Microspheres for controlled release drug delivery. Expert Opin Biol Ther 2004; 4: 35-51.
143. Jani C, McCarthy E, Florence T. Nanosphere and microsphere uptake via Peyer's patch: observation of the rate of uptake in the rat after a single dose. Int J Pharm 1992; 86: 239-246.
144. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral immunisation of biodegradable microspheres. Vaccine 1996; 14: 1677-1685.
145. Eldridge JH, Staas JK, Meulbroek JA, Mcghee JR, Tice TF, Gilley RM. Biodegradable microspheres as a vaccine delivery system. Mol Immurnol 1991; 28: 287-294.
146. Xuamano JC, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD, et al. Helper T-cell subsets for immunoglobulin-a responses - oral immunization with tetanus toxoid and choleratoxin as adjuvant selectively induces Th2 cells in mucosa-associated tissues. J Exp Med 1993; 178: 1309-1320.
147. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116: 804-812.
148. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51: 634-640.
149. Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R, et al. Safety and efficacy of E-coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002; 21: 194-201.
150. Durrani Z, Rijpkema S. Orogastric vaccination of guinea pigs with Helicobacter pylori sonicate and a high dose of cholera toxin lowers the burden of infection. FEMS Immunol Med Microbiol 2003; 36: 169-173.
151. Keenan JI, Rijpkema SG, Durrani Z, Roake JA. Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens. FEMS Immunol Med Microbiol 2003; 36: 199-205.
152. Kim SY, Doh HJ, Ahn JS, Ha YJ, Jang MH, Chung SI, Park HJ. Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D, L-lactide-co-glycolide) microparticles. Vaccine 1999; 17: 607-616.
153. Ren J-M. Zou Q-M, Wang F-K, He Q, Chen W, Zen W-K. PELA microspheres loaded H. pylori lysates and their mucosal immune response. World J Gastroenterol 2002; 8: 1098-1102.
154. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21: 341-346.
155. Johansson EL, Berquist C, Edebo A, Johansson C, Svennerholm AM. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004; 22: 984-990.
156. Kleanthous H, Myers GA, Georgakopoulos KM, Tibbitts TJ, Ingrassia JW, Gray HL, et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun 1998; 66: 2879-2886.
157. Marchetti M, Rossi M, Gianelli V, Giuliani MM, Pizza M, Censini S, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998; 16: 33-37.
158. Vajdy M, Singh M, Ugozzoli M, Briones M, Soenawan E, Cuadra L, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunol 2003; 100: 86-94.
159. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Rel 2001; 70: 267-276.
160. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69: 3581-3590.
161. Rugiero P, Peppoloni S, Rappuoli R, Del Guidice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microb Infect 2003; 5: 749-756.
162. Jiang W, Baker HJ, Smith BF. Mucosal immunisation with Helicobacter, CgG DNA and cholera toxin is protective. Infect Immun 2003; 71: 40-46.
163. Sommer F, Wilken H, Faller G, Lohoff M. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 2004; 72: 1029-1035.
164. Novak MJ, Smythies LE, McPherson SA, Smith PD, Morrow CD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Vaccine 1999; 17: 2384-2391.
165. Polo JM, Dubensky Jr TW. Virus-based vectors for human vaccine applications. Drug Discovery Today 2002; 7: 719-727.
166. Gomez-Duarte OG, Lucas B, Yan Z-X, Panthel K, Haas R, Meyer TF. Protection of mice against gastric colonization by Helicobacter pylori by single dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998; 16: 460-471.
167. Corthesy-Theulaz IE, Hopkins S, Bachmann D, Sladinger PF, Porta N, Haas R, et al. Mice are protected from Helicobacter pylori by nasal immunization with attenuated Salmonella typhimurium phoPC expressing urease A and B subunits. Infect Immun 1998; 66: 581-586.
168. Pasetti MF, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 2003; 21: 401-418.
169. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 2000; 18: 449-459.
170. Angelakopoulos H. Hahmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68: 2135-2141.
171. Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2002; 20: 845-852.
172. Londoño-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK, et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun 2002; 70: 5096-5106.
173. Miyashita M, Joh T, Watanabe K, Todoroki I, Seno K, Ohara H, et al. Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori catalase. Vaccine 2002; 20: 2336-2342.
174. Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 2004; 57: 19-34.
175. Chan FK. COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. Curr Pharm Design 2003; 9(27): 2213-9.
176. Jiang XH, Wong BC. Cyclooxygenase-2 inhibition and gastric cancer. Curr Pharm Design 2003; 9(27): 2281-8.
177. Legrain P, Strosberg D. Protein interaction domain mapping for the selection of validated targets and lead compounds in the anti-infectious area. Curr Pharm Design 2002; 8(13): 1189-98.